Holen Sie sich die Stockscreener-App
4.595
0.54%
-0.025
Schlusskurs vom Vortag:
$4.62
Offen:
$4.59
24-Stunden-Volumen:
176.02K
Relative Volume:
0.14
Marktkapitalisierung:
$597.92M
Einnahmen:
$204.17M
Nettoeinkommen (Verlust:
$-74.00M
KGV:
-7.9567
EPS:
-0.5775
Netto-Cashflow:
$-12.84M
1W Leistung:
-2.03%
1M Leistung:
+9.40%
6M Leistung:
+5.39%
1J Leistung:
+16.92%
1-Tages-Spanne:
$4.55
$4.64
1-Wochen-Bereich:
$4.515
$4.77
52-Wochen-Spanne:
$3.28
$6.18
Cytek Biosciences Inc Stock (CTKB) Company Profile
Firmenname
Cytek Biosciences Inc
Sektor
Branche
Telefon
(877) 922-9835
Adresse
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.60 | 600.52M | 204.17M | -74.00M | -12.84M | -0.5775 |
ABT
Abbott Laboratories
|
106.02 | 182.59B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.81 | 118.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
273.46 | 106.03B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.59 | 65.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.44 | 49.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-05-09 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-31 | Herabstufung | Goldman | Buy → Sell |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-07-19 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
Alle ansehen
Cytek Biosciences Inc Aktie (CTKB) Neueste Nachrichten
Sysmex Europe SE And Cytek Biosciences, Inc Collaborate To Expand Access To Advanced Clinical Flow Cytometry - marketscreener.com
Sysmex Europe SE and Cytek Biosciences Announce Strategic Collaboration to Expand Clinical Flow Cytometry Access Across Europe - Quiver Quantitative
Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry - Yahoo! Finance Canada
Cytek’s (CTKB) Instruments Keep Selling While Losses Keep Growing - Yahoo Finance
Cytek Biosciences Showcases Advanced Spectral Flow Cytometry Solutions At Escca and Iccs - marketscreener.com
Cytek Biosciences (CTKB) officer plans $146K share sale - Stock Titan
Cytek Biosciences stock holds near recent levels as investor conferences approach - AD HOC NEWS
Cytek Biosciences to Participate in Upcoming Investor Conferences - Yahoo Finance
Cytek Owes Beckman Coulter $56 Million at Patent Jury Trial (2) - news.bloomberglaw.com
Cytek (CTKB) Earnings Report: EPS Clears the Reported Estimate in Latest Trading; Price Reaction: Shares Finish 3.22% Up in the Latest SessionPre-Announcement Alert - vinanet.vn
Cytek Hit With $56M Verdict For Infringing Cell-Sorting Patent - Law360
Cytek Biosciences wins on three of four patent claims - Investing.com
Cytek Biosciences wins on three of four patent claims By Investing.com - Investing.com Nigeria
Cytek owes Beckman Coulter $56 mln in cell-analysis patent case, US jury says - Reuters
Cytek products remain available worldwide after jury awards $36M in royalties - Stock Titan
Cytek Biosciences CFO William D. McCombe Executes RSU Vesting and Tax Withholding Transactions - Kalkine Media
Cytek Biosciences Director Glenn P. Muir Converts 3,086 RSUs to Common Stock on August 18, 2026 - Kalkine Media
Cytek Biosciences (CTKB) CEO gets 120K shares, surrenders some for taxes - Stock Titan
Cytek Biosciences (NASDAQ: CTKB) director gains 3,086 no-cost shares - Stock Titan
Cytek Biosciences (CTKB) director now holds 28,499 shares - Stock Titan
Cytek Biosciences (CTKB) CTO gets 33,270 shares, surrenders some for taxes - Stock Titan
Cytek (CTKB) Quarterly Figures: EPS Prints Above Forecast in the Latest Session; Stock Move: Shares Finish 0.96% HigherEstimate Dispersion - vinanet.vn
Cytek Biosciences CEO Wenbin Jiang Completes RSU Vesting and Tax Withholding Share Surrender - kalkinemedia.com
Cytek Biosciences Balances Growth With Profit Pressures - TipRanks
Cytek (CTKB) Q2 2026 Earnings Call Transcript - AOL.com
Cytek Biosciences (CTKB) awards 241,416 RSUs and 127,118 options to top lawyer - Stock Titan
Cytek Biosciences: Recurring Revenue Reaches 35% Of Sales As Installed Base Approaches 4,000 Instruments - Pulse 2.0
Cytek Biosciences launches Aurora Evo system to drive high-throughput research and small particle detection - Traders Union
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Cytek Biosciences (NASDAQ:CTKB) Trading 8.5% HigherShould You Buy? - MarketBeat
Cytek Biosciences, Inc. (8EQ.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Cytek Biosciences (CTKB) and Sight Sciences (SGHT) - The Globe and Mail
Cytek Biosciences, Inc. (CTKB) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore
Cytek Biosciences (CTKB) holders report over 7% stakes in Schedule 13G/A - Stock Titan
Cytek Biosciences, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Morgan Stanley Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Cuts Target Price to $5 - Moomoo
TD Cowen Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Maintains Target Price $5 - Moomoo
Cytek Biosciences Reports Second Quarter 2026 Financial Results - The Manila Times
Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ... - Yahoo! Finance Canada
Cytek Biosciences Q2 2026 Earnings Report: Financial Highlights, Revenue Growth, and Investor Insights - Minichart
CTKB Looks 28.3% Undervalued on GF Value™ Despite Unprofitable S - GuruFocus
Cytek Biosciences (NASDAQ:CTKB) Posts Earnings Results, Hits Estimates - MarketBeat
Cytek Biosciences Q2 Earnings Call Highlights - MarketBeat
Cytek Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Cytek Biosciences earnings missed, revenue fell short of estimates - Investing.com
Earnings call transcript: Cytek Biosciences posts q2 2026 revenue growth, shares fall - Investing.com Nigeria
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Cytek Biosciences (CTKB) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss - Quiver Quantitative
Cytek Biosciences, Inc. 2Q 2026: Revenue $48.14M, EPS ($0.09) — 10-Q Summary - TradingView
Cytek Biosciences Q2 revenue slightly misses estimates - TradingView
Cytek Biosciences Q2 2026: Revenue $48.1M, Gross Profit $28.3M, Net Loss $12.2M - TradingView
Finanzdaten der Cytek Biosciences Inc-Aktie (CTKB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):